Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML

Michael Deininger, MD, PhD, The Medical College of Wisconsin, Milwaukee, WI, compares the safety of bosutinib and asciminib in heavily pre-treated patients with chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Novartis, BMS, Incyte, Takeda, Blueprint, Cogent, CTI.